表紙
市場調査レポート

アレルギー性鼻炎:治療薬の予測と世界市場の分析

PharmaPoint: Allergic Rhinitis - Global Drug Forecast and Market Analysis to 2024

発行 GlobalData 商品コード 345972
出版日 ページ情報 英文 280 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
アレルギー性鼻炎:治療薬の予測と世界市場の分析 PharmaPoint: Allergic Rhinitis - Global Drug Forecast and Market Analysis to 2024
出版日: 2015年09月01日 ページ情報: 英文 280 Pages
概要

最新の予測調査によれば、欧州諸国の総人口の50%以上が2027年までに、何らかのアレルギー症状に悩むようになる、と見られています。他方、アレルギー性鼻炎 (AR) に関しては、標準的な治療法の開発・普及によって市場が成熟化し、成長率も低下する見通しです。また、患者の多くが現在の治療薬に不満を抱えていることや、ジェネリック医薬品が普及し始めたことも、市場縮小を促す要因となっています。AR治療薬も処方薬からOTC (市販薬) へと移行し、調剤薬局ではなく一般薬局で購入する患者が増えるなど、購入チャネルも変化の只中にあります。そのような状況を受けて、2024年までに新たに開発される治療薬はわずか2種類にとどまっています。

当レポートでは、全世界のアレルギー性鼻炎 (以下AR) 治療薬市場の現状と将来展望について分析し、疾患の概要や今後の疫学的予測、主要国での予防体性、主要企業のプロファイルと代表的製品、市場のアンメットニーズと将来的な機会、現在治験中のパイプライン製品の情報、今後の市場規模と影響要因などを調査しております。

第1章 目次

第2章 イントロダクション

病因 病態生理・病歴 黒色腫のバイオマーカー ▼臨床病期

第3章 疾患の概要

  • 病因・病態
  • 症状
  • 分類
    • 季節性・通年性AR
    • ARIAによるARの分類
  • 予後
  • 生活の質 (QoL)

第4章 疫学

  • 疾患の背景事情
  • リスク要因と共存症
    • ARの家族歴:成人・小児を問わず、ARの強力な予見要素となる
    • アレルゲンへの曝露:AR発症リスクの増大
    • 都市部での生活による、AR罹患率の上昇
    • 併存症
  • 世界各地での過去の傾向
    • 米国
    • 欧州主要5ヶ国
    • 日本
  • 予測手法
    • 利用した情報源
    • 利用しなかった情報源
    • 予測の前提条件と手法
  • 疫学的予測 (今後11年間分)
    • ARの発症件数 (総数)
    • ARの発症件数 (年齢別)
    • ARの発症件数 (男女別)
    • ARの年齢調整済み発症率
    • ARの有病率数の分布状況:重症度別
    • ARの有病率数の分布状況:重度別
    • ARの有病率数の分布状況:特定のアレルギー症状患者の場合
  • 議論
    • 疫学上の予測・考察
    • 分析の限界
    • 分析の強み

第5章 疾患の管理

  • 診断・治療の概要
    • 診断
    • 治療のガイドラインと、主な処方薬
    • 診療診療
  • 米国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本

第6章 競争環境

  • 概要
  • 経口H1抗ヒスタミン剤
    • 概要
    • 効能
    • 安全性
    • SWOT分析
    • 予測
  • 経鼻抗ヒスタミン剤
  • 経鼻コスチコステロイド
  • 経鼻コスチコステロイド/抗ヒスタミン剤の配合
  • 充血緩和剤
  • 経鼻抗コリン薬
  • ロイコトリエン受容体の拮抗薬
  • クロモン
  • トロンボキサンA2受容体の拮抗薬
  • TH2サイトカインの阻害剤

第7章 市場機会とアンメットニーズ

  • 概要
  • 薬剤師の教育
    • アンメットニーズ
    • ギャップ分析
    • 市場機会
  • 経鼻コスチコステロイド・抗ヒスタミン剤投与に際しての服薬遵守
  • 利便性がより高く、患者への負担を減らした免疫療法
  • プライマリーケア向けの医師教育

第8章 パイプライン評価

  • 治験中の有望な医薬品
    • S-555739
    • HP-3060

第9章 現在・将来の市場参入企業

  • 概要
  • 企業戦略の概要
  • 主要企業
    • Merck & Co.
    • GlaxoSmithKline
    • 大日本住友製薬
    • Sanofi
    • Teva
    • Meda AB

第10章 市場の見通し

  • 世界市場
    • 市場予測
    • 市場促進・阻害要因:世界的課題
  • 米国
    • 市場予測
    • 近年の主な出来事
    • 市場促進・阻害要因
  • 欧州主要5ヶ国
  • 日本

第11章 付録

図表一覧

目次
Product Code: GDHC113PIDR

Allergic Rhinitis (AR) is becoming an increasingly prevalent condition, with the most common form being moderate to severe in nature (Baena-Cagnani et al., 2015). According to the European Academy of Allergy and Clinical Immunology (EAACI), 50% of Europeans will suffer from an allergy by 2027 (Papadopoulos et al., 2012). The allergic rhinitis (AR) market has declined very slowly over the past decade, as has it become saturated with relatively efficacious standard therapies, such as antihistamines (AHs), intranasal corticosteroids (INCS), and leukotriene receptor antagonists (LRAs), and has also been facing increasing generic competition. Despite the rising prevalence of AR, and a large patient population that is dissatisfied with the current treatment options, the market size for symptomatic therapies alone is set to shrink, as the remaining branded products lose patent protection. There is an increasing shift in the transfer of prescription AR products to over-the-counter (OTC) status, which is driving patients to pharmacies rather than to physicians, further diluting the prescription AR market. The immense, crowded generic AR market has been largely unappealing to drug manufacturers. Consequently, only two symptomatic therapies are expected to launch before 2024.

Highlights

Key Questions Answered

  • Allergic Rhinitis symptoms can be controlled in the majority of patients using the current standard therapies. Nevertheless, in around 20% of people with allergic rhinitis, the disease remains symptomatic and inadequately controlled. Therefore, there are considerably high unmet needs within the indication. What are the main unmet needs in this market?
  • The current late-stage allergic rhinitis pipeline is sparse. Will the late-stage symptomatic drugs make a significant impact on the allergic rhinitis market? What strategies are drug developers undertaking to penetrate this difficult but potentially very lucrative market? How will immunotherapies affect the market landscape?
  • The prevalence of environmental diseases, including allergic rhinitis, is increasing worldwide, with an estimated 46 million US citizens are likely to suffer from allergic rhinitis in 2024. How will epidemiological changes impact the growth of the future market?

Key Findings

  • The main driver of growth in the AR market will be the introduction of several AIT tablets: Merck's Grastek (grass), Ragwitek (ragweed), and Mitizax (house dust mite [HDM]) tablets, as well as Greer's Oralair (grass) in the US. These new products overcome the inconvenience of conventional subcutaneous immunotherapies (SCITs).
  • The major global barrier for the AR market will be the increasing push for patients to self-medicate using OTC drugs will decrease the prescription AR drug market size.
  • There is little room for new entrants, as the market is well-served by a wealth of symptomatic therapies. Since the competition is increasing, the market for AR therapies is becoming increasingly less lucrative. Also, there are currently no breakthrough symptomatic therapy products in clinical development.
  • The remaining clinical unmet needs in this market include the requirement for more efficacious products, and the underserved area of causative therapies, such as immunotherapies, which target the underlying cause of the disease.

Scope

  • Overview of AR, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized AR therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the AR therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global AR therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global AR therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AR therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global AR therapeutics market from 2014-2024.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
  • 3.2. Symptoms
  • 3.3. Classification
    • 3.3.1. Seasonal and Perennial AR
    • 3.3.2. ARIA Classification of AR
  • 3.4. Diagnosis
  • 3.5. Quality of Life

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
    • 4.2.1. A family history of AR is a strong predictor for AR in children and adults
    • 4.2.2. Exposure to allergens in the environment increases the risk for AR
    • 4.2.3. Urban living elevates the risk for AR
    • 4.2.4. Comorbidities
  • 4.3. Global and Historical Trends
    • 4.3.1. US
    • 4.3.2. 5EU
    • 4.3.3. Japan
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Sources Not Used
    • 4.4.3. Forecast Assumptions and Methods
  • 4.5. Epidemiological Forecast for AR (2013-2023)
    • 4.5.1. Total Prevalent Cases of AR
    • 4.5.2. Age-Specific Total Prevalent Cases of AR
    • 4.5.3. Sex-Specific Total Prevalent Cases of AR
    • 4.5.4. Age-Standardized Total Prevalence of AR
    • 4.5.5. Distribution of Total Prevalent Cases of AR by Severity
    • 4.5.6. Distribution of Total Prevalent Cases of AR by Type
    • 4.5.7. Distribution of Total Prevalent Cases of AR Sensitized to Specific Allergens
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis and Treatment Overview
    • 5.1.1. Diagnosis
    • 5.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 5.1.3. Clinical Practice
  • 5.2. US
  • 5.3. France
  • 5.4. Germany
  • 5.5. Italy
  • 5.6. Spain
  • 5.7. UK
  • 5.8. Japan

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Oral H1 Antihistamines
    • 6.2.1. Overview
    • 6.2.2. Efficacy
    • 6.2.3. Safety
    • 6.2.4. SWOT Analysis
    • 6.2.5. Forecast
  • 6.3. Intranasal Antihistamines
  • 6.4. Intranasal Corticosteroids
    • 6.4.1. Overview
    • 6.4.2. Efficacy
    • 6.4.3. Safety
    • 6.4.4. SWOT Analysis
    • 6.4.5. Forecast
  • 6.5. Combination Intranasal Corticosteroids/Antihistamines
    • 6.5.1. Dymista
  • 6.6. Decongestants
    • 6.6.1. Overview
  • 6.7. Intranasal Anticholinergics
    • 6.7.1. Overview
  • 6.8. Leukotriene Receptor Antagonists
    • 6.8.1. Overview
  • 6.9. Cromones
    • 6.9.1. Overview
  • 6.10. Thromboxane A2 Receptor Antagonists
    • 6.10.1. Overview
  • 6.11. TH2. Cytokine Inhibitors
    • 6.11.1. Overview

7. Unmet Need and Opportunity

  • 7.1. Overview
  • 7.2. Pharmacist Education
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. Patient Compliance With Intranasal Corticosteroids and Antihistamines
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity
  • 7.4. More Convenient and More Patient-Friendly Immunotherapies
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. Primary Care Physician Education
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity

8. Pipeline Assessment

  • 8.1. Promising Drugs in Clinical Development
    • 8.1.1. S-555739
    • 8.1.2. HP-3060

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Major Companies
    • 9.3.1. Merck & Co.
    • 9.3.2. GlaxoSmithKline
    • 9.3.3. Sumitomo Dainippon Pharma
    • 9.3.4. Sanofi
    • 9.3.5. Teva
    • 9.3.6. Meda AB

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. United States
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. 5EU
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Japan
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Pediatric Allergic Rhinitis Population
    • 11.4.2. Diagnosed AR Patients
    • 11.4.3. Percentage of Drug-Treated Patients
    • 11.4.4. Drugs Included in Each Therapeutic Class
    • 11.4.5. Launch and Patent Expiry Dates
    • 11.4.6. 1General Pricing Assumptions
    • 11.4.7. Individual Drug Assumptions
    • 11.4.8. Generic Erosion
    • 11.4.9. Pricing of Pipeline Agents
  • 11.5. Physicians and Specialists Included in This Study
  • 11.6. About the Authors
    • 11.6.1. Analyst
    • 11.6.2. Therapy Area Director
    • 11.6.3. Epidemiologist
    • 11.6.4. Global Head of Healthcare
  • 11.7. About GlobalData
  • 11.8. Disclaimer

List of Tables

  • Table 1: Airborne Allergens That Cause AR
  • Table 2: Common Symptoms of AR
  • Table 3: Classification of AR Based on Etiological Type and Severity
  • Table 4: Common Risk Factors and Comorbidities for AR
  • Table 5: Prevalence of the Most Frequently Occurring Comorbidities in People with AR
  • Table 6: Age-Specific Prevalence of Hay Fever from the 2011 NHIS Survey
  • Table 7: Self-Reported Total Prevalence (%) of AR in the 5EU, Age 20-44 Years
  • Table 8: Total Prevalence (%) of AR in the EU, Age 6-14 Years
  • Table 9: 7MM, Sources of Data Used to Forecast the Total Prevalent Cases of AR
  • Table 10: 7MM, Sources Excluded from the Epidemiological Forecast for the Total Prevalent Cases of AR
  • Table 11: 7MM, Total Prevalent Cases of AR, Both Sexes, Ages ≥18 Years, N, 2013-2023
  • Table 12: 7MM, Age-Specific Total Prevalent Cases of AR, Both Sexes, N (Row %), 2013
  • Table 13: 7MM, Sex-Specific Total Prevalent Cases of AR, Ages ≥18 Years, N (Row %), 2013
  • Table 14: 7MM, Distribution of Total Prevalent Cases of AR by Severity, Both Sexes, N (Row %), 2013
  • Table 15: 7MM, Distribution of Total Prevalent Cases of AR by Type, Both Sexes, N (Row %), 2013
  • Table 16: 7MM, Proportion of Total Prevalent AR Cases Sensitized to Specific Allergens, Both Sexes, %, 2013
  • Table 17: Treatment Guidelines for AR
  • Table 18: Most Commonly Prescribed Drugs for AR in the 7MM by Class, 2014
  • Table 19: Major Brands of INCS
  • Table 20: Management of AR, Country Profile - US
  • Table 21: Management of AR, Country Profile - France
  • Table 22: Management of AR, Country Profile - Germany
  • Table 23: Management of AR, Country Profile - Italy
  • Table 24: Management of AR Country Profile - Spain
  • Table 25: Management of AR Country Profile - UK
  • Table 26: Management of AR, Country Profile - Japan
  • Table 27: Effects of Main Drug Classes on AR Symptoms
  • Table 28: Leading Branded Drugs Used to Treat AR, 2014
  • Table 29: Major Brands of Second- and Third-Generation Non-Sedating AHs
  • Table 30: Product Profile - AHs
  • Table 31: Efficacy of Bilastine in Symptomatic SAR Patients Age 12-70 Years
  • Table 32: Safety of Bilastine in Symptomatic SAR Patients Age 12-70 Years
  • Table 33: Oral AHs SWOT Analysis, 2014
  • Table 34: Global Sales Forecasts ($m) for Oral AHs, 2014-2024
  • Table 35: Major Brands of Intranasal Ahs
  • Table 36: Major Brands of INCS
  • Table 37: Product Profile - INCS
  • Table 38: Efficacy of FP ANS and BDP ANS in AR Patients Age 18-72 Years
  • Table 39: Safety Profile of FP ANS and BDP ANS in AR Patients Age 18-72 Years
  • Table 40: INCS SWOT Analysis, 2014
  • Table 41: Global Sales Forecasts ($m) for INCS, 2014-2024
  • Table 42: Product Profile - Dymista
  • Table 43: Efficacy of Dymista
  • Table 44: Safety of Dymista
  • Table 45: Dymista SWOT Analysis, 2014
  • Table 46: Global Sales Forecasts ($m) for Dymista, 2014-2024
  • Table 47: Unmet Need and Opportunity in AR
  • Table 48: Late-Stage Pipeline for AR, 2014
  • Table 49: Product Profile - S-555739
  • Table 50: Completed Clinical Trials of S-555739 in AR Patients
  • Table 51: S-555739 SWOT Analysis, 2014
  • Table 52: Global Sales Forecasts ($) for S-555739, 2014-2024
  • Table 53: Product Profile - HP-3060
  • Table 54: HP-3060 SWOT Analysis, 2014
  • Table 55: Global Sales Forecasts ($) for HP-3060, 2014-2024
  • Table 56: Major Companies in the AR Market and Their Portfolios, 2014
  • Table 57: Merck's AR Portfolio Assessment, 2014
  • Table 58: GSK's AR Portfolio Assessment, 2014
  • Table 59: Sumitomo Dainippon Pharma's AR Portfolio Assessment, 2014
  • Table 60: Sanofi's AR Portfolio Assessment, 2014
  • Table 61: Teva's AR Portfolio Assessment, 2014
  • Table 62: Meda's AR Portfolio Assessment, 2014
  • Table 63: Global Sales Forecasts ($m) for AR, 2014-2024
  • Table 64: Global AR Market - Drivers and Barriers, 2014-2024
  • Table 65: Sales Forecasts ($m) for AR in the US, 2014-2024
  • Table 66: Key Events Impacting Sales for AR in the US, 2014-2024
  • Table 67: AR Market - Drivers and Barriers in the US, 2014-2024
  • Table 68: Sales Forecasts ($m) for AR in the 5EU, 2014-2024
  • Table 69: Key Events Impacting Sales for AR in the 5EU, 2014-2024
  • Table 70: AR Market - Drivers and Barriers in the 5EU, 2014
  • Table 71: Sales Forecasts ($) for AR in Japan, 2014-2024
  • Table 72: Key Events Impacting Sales for AR in Japan, 2014-2024
  • Table 73: AR Market - Drivers and Barriers in Japan, 2014-2024
  • Table 74: Abbreviations
  • Table 75: Key Launch Dates of the Currently Available AR Therapies
  • Table 76: Key Loss of Exclusivity Dates of the Currently Available AR Therapies
  • Table 77: High-Prescribing Physicians (non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: Immunological Mechanisms Involved in the Early- and Late-Phase Allergic Response
  • Figure 2: ARIA Classification of AR by Duration of Symptoms and Severity
  • Figure 3: 7MM, Total Prevalent Cases of AR, Both Sexes, Age ≥18 Years, N, 2013-2023
  • Figure 4: 7MM, Age-Specific Total Prevalent Cases of AR, Both Sexes, N, 2013
  • Figure 5: 7MM, Sex-Specific Total Prevalent Cases of AR, Ages ≥18 Years, N, 2013
  • Figure 6: 7MM, Age-Standardized Total Prevalence (%) of AR, Ages ≥18 Years, by Sex, 2013
  • Figure 7: Algorithm Used for the Management of AR in the 7MM*
  • Figure 8: Company Portfolio Gap Analysis in AR, 2014-2024
  • Figure 9: Global Sales for AR by Region, 2014-2024
  • Figure 10: Sales for AR in the US by Drug Class, 2014-2024
  • Figure 11: Sales for AR in the 5EU by Drug Class, 2014-2024
  • Figure 12: Sales for AR in Japan by Drug Class, 2014-2024
Back to Top